• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22831 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2003     Canadian Task Force on Preventive Health Care (CTFPHC) Screening for type 2 diabetes to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care
2013     NIHR Health Technology Assessment programme Screening for type 2 diabetes: a short report for the National Screening Committee
2007     NIHR Health Technology Assessment programme Screening for type 2 diabetes: literature review and economic modelling
2008     Agency for Healthcare Research and Quality (AHRQ) Screening for type 2 diabetes: update of 2003 systematic evidence review for the U.S. Preventive Services Task Force
2008     Agency for Healthcare Research and Quality (AHRQ) Screening for type 2 diabetes: update of 2003 systematic evidence review for the U.S. Preventive Services Task Force.
2006     Blue Cross Blue Shield Association (BCBS) Screening for vertebral fracture with dual x-ray absorptiometry
2011     Agency for Healthcare Research and Quality (AHRQ) Screening for visual impairment in children ages 1-5 years: systematic review to update the 2004 U.S. Preventive Services Task Force Recommendation
2004     Agency for Healthcare Research and Quality (AHRQ) Screening for visual impairment in children younger than age 5 years: a systematic evidence review for the U.S. Preventive Services Task Force
2009     Agency for Healthcare Research and Quality (AHRQ) Screening for visual impairment in older adults: systematic review to update the 1996 U.S. Preventive Services Task Force recommendation
2014     Agency for Healthcare Research and Quality (AHRQ) Screening for vitamin D deficiency: systematic review for the U.S. Preventive Services Task Force Recommendation
2006     Quality Improvement Scotland (NHS QIS ) Screening hips of newborns in Scotland: a Health Technology Assessment scoping report
2008     Agency for Healthcare Research and Quality (AHRQ) Screening in primary care settings for illicit drug use: assessment of screening instruments - a supplemental evidence update for the U.S. Preventive Services Task Force
2008     Agency for Healthcare Research and Quality (AHRQ) Screening in primary care settings for illicit drug use: assessment of screening instruments - a supplemental evidence update for the U.S. Preventive Services Task Force
2008     Agency for Healthcare Research and Quality (AHRQ) Screening in primary care settings for illicit drug use: staged systematic review for the U.S. Preventive Services Task Force
2008     Agency for Healthcare Research and Quality (AHRQ) Screening in primary care settings for illicit drug use: staged systematic review for the United States Preventive Services Task Force
2005     NIHR Health Technology Assessment programme Screening in the first year of life for congenital heart disease: review and cost-effectiveness analysis - secondary research
2007     Medical Advisory Secretariat (MAS) Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis
2002     HAYES, Inc. Screening mammography for women at average risk for breast cancer
2005     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) Screening mammography: a reassessment
2009     Medical Advisory Secretariat (MAS) Screening methods for early detection of colorectal cancers and polyps: summary of evidence-based analyses
2007     Institute of Health Economics (IHE) Screening newborns for cystic fibrosis
2007     Institute of Health Economics (IHE) Screening newborns for hearing: the use of the automated auditory brainstem response and otoacoustic emissions tests for newborn hearing screening
1996     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Screening of cervical intraepithelial neoplasia (CIN) - primary research
2018     European Network for Health Technology Assessment (EUnetHTA) Screening of fetal trisomies 21, 18 and 13 by non invasive prenatal testing
2004     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Screening of osteoporosis by densitometry by ultrasound versus ionising techniques by X-rays. Evaluation of clinical utility and usage status in Spain
2014     Malaysian Health Technology Assessment (MaHTAS) Screening of pregnant women aged 40 years old and above for cardiac abnormalities using electrocardiography (ECG) to prevent maternal mortality
2004     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Screening of the hearing of newborns - systematic review of medical efficacy and economic efficiency
2006     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Screening of the hearing of newborns - Update
2005     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Screening on urogenital chlamydia trachomatis
1998     New Zealand Health Technology Assessment (NZHTA) Screening programmes for the detection of otitis media with effusion and conductive hearing loss in pre-school and new entrant school children: a critical appraisal of the literature
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening programs for asymptomatic unruptured intracranial aneurysms: review of clinical effectiveness, cost-effectiveness, and evidence-based guidelines
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Screening programs for children and adolescents from 6 to 18 years. Results on selected countries, Austrian screening programmes and recommendations from evidence-based guidelines
1997     Wessex Institute for Health Research and Development (WIHRD) Screening staff for methicillin resistant Staphylococcus aureus (MRSA)
2006     New Zealand Health Technology Assessment (NZHTA) Screening strategies for antenatal Down syndrome screening
2017     NIHR Health Technology Assessment programme Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis
2001     Canadian Task Force on Preventive Health Care (CTFPHC) Screening strategies for colorectal cancer: systematic review and recommendations
2012     Penn Medicine Center for Evidence-based Practice (CEP) Screening tests for aspiration and dysphagia
2009     Penn Medicine Center for Evidence-based Practice (CEP) Screening tests for recent heavy alcohol use
2009     NIHR Health Technology Assessment programme Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening tools compared to parental concern for identifying speech and language delays in preschool children: a review of the diagnostic accuracy
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening tools to identify adults with cognitive impairment associated with a cerebrovascular accident or traumatic brain injury: diagnostic accuracy
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening tools to identify adults with cognitive impairment associated with a neurological impairment: diagnostic accuracy
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening tools to identify adults with cognitive impairment associated with dementia: diagnostic accuracy
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening tools to identify adults with mild cognitive impairment not associated with dementia: a review of diagnostic accuracy, effectiveness and guidelines
2007     Quality Improvement Scotland (NHS QIS ) Screening tools, detoxification and vitamin supplementation for alcohol dependence
2018     NIHR Health Technology Assessment programme Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation
2018     NIHR Health Technology Assessment programme Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation
2012     Agency for Healthcare Research and Quality (AHRQ) Screening women for intimate partner violence and elderly and vulnerable adults for abuse: systematic review to update the 2004 U.S. Preventive Services Task Force Recommendation.
2012     Agency for Healthcare Research and Quality (AHRQ) Screening, behavioral counseling, and referral in primary care to reduce alcohol misuse
2010     HAYES, Inc. Screening, brief intervention, and referral to treatment (SBIRT) for alcohol misuse
2010     HAYES, Inc. Screening, brief intervention, and referral to treatment (sbirt) for illicit drug use
2012     HAYES, Inc. Screening, brief intervention, and referral to treatment (SBIRT) for substance use among pregnant women
2012     HAYES, Inc. Screening, Brief Intervention, and Referral to Treatment (SBIRT) using remote interventions for alcohol misuse
2017     NIHR Health Technology Assessment programme Seal or Varnish? A randomised controlled trial to determine the relative cost and effectiveness of pit and fissure sealant and fluoride varnish in preventing dental decay
1994     U. S. Congress. Office of Technology Assessment (OTA) Searching for evidence: identifying health technologies that work
2008     Health Council of the Netherlands Gezondheidsraad (GR) Searchlight on radiotherapy. A vision for 2015
2020     NIHR Health Technology Assessment programme Seasonal Influenza Vaccination Effectiveness II (SIVE II): use of a large national primary care and laboratory-linked dataset to evaluate live attenuated and trivalent inactivated influenza vaccination effectiveness
2013     Belgian Health Care Knowledge Centre (KCE) Seasonal influenza vaccination: prioritizing children or other target groups? Part II: cost-effectiveness analysis
2013     NIHR Health Services and Delivery Research programme Seasonal Influenza Vaccine Effectiveness (SIVE): an observational retrospective cohort study - exploitation of a unique community-based national-linked database to determine the effectiveness of the seasonal trivalent influenza vaccine
2011     Penn Medicine Center for Evidence-based Practice (CEP) Seasonal variation in readmission rates
2016     HAYES, Inc. Sebelipase Alfa (Kanuma) for treatment of lysosomal acid lipase deficiency
2012     NIHR Horizon Scanning Centre (NIHR HSC) Sebelipase alfa for lysosomal acid lipase deficiency
2024     National Institute for Health and Care Excellence (NICE) Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal). NICE technology appraisal guidance 961
2010     HAYES, Inc. Secca (Mederi Therapeutics Inc.) procedure for fecal incontinence
2017     NIHR Health Services and Delivery Research programme Seclusion and Psychiatric Intensive Care Evaluation Study (SPICES): combined qualitative and quantitative approaches to the uses and outcomes of coercive practices in mental health services
2004     Malaysian Health Technology Assessment Unit (MHTAU) Second generation endometrial ablation
2004     Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) Second generation endometrial ablation techniques
2015     Andalusian Health Technology Assessment Area (AETSA) Second generation prognostic genomic tests in early breast cancer: EndoPredict® y Prosigna™.
2014     Medical Services Advisory Committee (MSAC) Second Opinion for Morphological/Interpretive Pathology
2011     Agency for Healthcare Research and Quality (AHRQ) Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review
2018     Agency for Care Effectiveness (ACE) Second-generation antipsychotic injections for treating schizophrenia
2020     Scottish Health Technologies Group (SHTG) Second-generation colon capsule endoscopy (CCE-2) for the detection of colorectal polyps – SHTG Recommendation
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Second-line therapy for patients with diabetes inadequately controlled on metformin: a systematic review and cost-effectiveness analysis
2015     HAYES, Inc. Second-wave direct-acting antivirals for hepatitis C: ledipasvir-sofosbuvir
2014     HAYES, Inc. Second-wave direct-acting antivirals for hepatitis C: Simeprevir
2015     HAYES, Inc. Second-wave direct-acting antivirals for hepatitis C: Simeprevir
2015     HAYES, Inc. Second-wave direct-acting antivirals for hepatitis C: sofosbuvir
2014     HAYES, Inc. Second-wave direct-acting antivirals for hepatitis C: Sofosbuvir and Ledipasvir
2015     NIHR Health Services and Delivery Research programme Secondary analysis and literature review of community rehabilitation and intermediate care: an information resource
2007     National Institute for Health and Care Excellence (NICE) Secondary prevention in primary and secondary care for patients following a myocardial infarction
2002     NIHR Horizon Scanning Centre (NIHR HSC) Secretin for autism spectrum disorders - horizon scanning review
2012     NIHR Horizon Scanning Centre (NIHR HSC) Secukinumab for active and progressive psoriatic arthritis
2016     National Institute for Health and Care Excellence (NICE) Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors. NICE technology appraisal guidance 407
2012     NIHR Horizon Scanning Centre (NIHR HSC) Secukinumab for ankylosing spondylitis – second line
2012     NIHR Horizon Scanning Centre (NIHR HSC) Secukinumab for moderate to severe, active rheumatoid arthritis
2012     NIHR Horizon Scanning Centre (NIHR HSC) Secukinumab for plaque psoriasis
2021     Scottish Medicines Consortium (SMC) Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
2023     National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe hidradenitis suppurativa. NICE technology appraisal guidance 935
2015     NIHR Health Technology Assessment programme Secukinumab for treating moderate to severe plaque psoriasis
2021     National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe plaque psoriasis in children and young people. NICE technology appraisal guidance 734
2015     National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 350
2021     National Institute for Health and Care Excellence (NICE) Secukinumab for treating non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 719
2013     Penn Medicine Center for Evidence-based Practice (CEP) Securement devices for peripherally inserted central venous catheters (PICCs) and Midline catheters
2018     Penn Medicine Center for Evidence-based Practice (CEP) Securement of Arterial Catheters
2022     Swiss Federal Office of Public Health (FOPH) Sedative-hypnotic drugs for the treatment of primary chronic insomnia disorder
2002     University HealthSystem Consortium (UHC) Sedative/hypnotics
2020     Canary Health Service Seguridad, efectividad clínica y coste-efectividad de intervenciones para la prevención del delirium en el ingreso hospitalario
2020     Canary Health Service Seguridad, efectividad y coste-efectividad de los sistemas integrados de infusión subcutánea continua de insulina más sensor de monitorización continua de glucosa
2018     Canary Health Service Seguridad, efectividad y coste-efectividad del desfibrilador automático implantable subcutáneo en prevención primaria y secundaria de muerte súbita
2013     NIHR Health Technology Assessment programme SeHCAT (Tauroselcholic [75 selenium] acid) for the investigation of bile acid malabsorption (BAM) and measurement of bile acid pool loss